AgingResearch.NewsJoin free

REGENXBIO

CompanyUnited States

REGENXBIO develops one asset, in phase 3 (Surabgene Lomparvovec in neovascular age-related macular degeneration). Mostly gene therapy acting on VEGFA; based in the United States.

1
Asset
Furthest stage
Phase 3
0
Trials
1
Signal

Pipeline

1

  • Surabgene Lomparvovec

    Delivers a gene encoding an anti-VEGF antibody fragment to suppress abnormal retinal blood vessel growth and leakage.

    Phase 3, Gene therapy, VEGFA, neovascular age-related macular degeneration, wet age-related macular degeneration

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • People1
  • Signals2
  • Similar companies6

Intelligence